Astellas Pharma to transfer Intal rights to Sanofi-aventis
Astellas Pharma is also expected to transfer the manufacturing and marketing approval for all Intal products to Sanofi-aventis as of 1 October 2010. Intal is a chemical mediator
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.